CROS NT Continues to Represent BIAS Steering Committee

June 1, 2011 - PRLog -- Valeria Visonà, Head of Statistical Programming for CROS NT, was elected to the BIAS Steering Committee during the BIAS Congress in Turin, Italy this month.

BIAS, Biometristi Dell’Industria Associati (Biometrician Industry Associates), is a prestigious Italian organization comprised of statisticians and data managers. The committee works with pharmaceutical companies and Contract Research Organizations as well as with universities and scientific companies. BIAS is made up of professionals in the industry who take a problem-solving approach to risks and changes affecting the profession of statisticians and data managers.

Valeria joins fellow colleague, Lisa Comarella, Head of Statistical Methodology, and Paolo Morelli, CEO and Statistician, on the BIAS Steering Committee.

“For me it is an opportunity to expand the views and knowledge of the world of clinical trials by having the chance to meet with others in the industry (other CROs, pharmaceutical companies, hospitals, etc) and to suggest to the committee themes and topics of study which we could also maybe use internally at CROS”, says Valeria.

Valeria has been a Senior Statistician at CROS NT since 2009 and is now the Head of Statistical Programming. She has been a member of BIAS since 2008.

Related Links:
BIAS: http://www.bias-it.org/comitato.htm

# # #

CROS NT Group, an international Contract Research Organisation (CRO), with headquarters in Verona, Italy, has built a strong heritage in biostatistics as well as providing clinical data management, medical communication, pharmacovigilance, and technology solutions to the life science industry. Founded in 1992, CROS NT is well-established in delivering quality, timely, and cost effective service. The ARITHMOS branch of CROS NT provides IT solutions to the pharmaceutical and biotechnology industries such as hosting, data integration, computer system validation and software development to increase the success rate of clinical trials and drug safety development processes.